Synagis palivizumab: Phase IV data; Marketed

In an outcomes survey of 2,830 patients treated with Synagis in the U.S. during the 1999-2000 RSV season, 2.4 percent of the patients were hospitalized with an RSV lower respiratory infection. Similar...